{"data":[{"PressReleaseId":"1701","PressReleaseDate":"November 07, 2024","Headline":"Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results","ShortBody":"On track to initiate a Phase 3 program for Company\u2019s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained improvement at Weeks 36 and 48 Cash, cash equivalents and marketable securities of $234.4 million as of September 30, 2024; cash runway expected into 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today reported financial results for the third quarter ended September 30, 2024. \u201cThis quarter, we continued to advance our late-stage pipeline as part of our goal to bring new potential treatments to communities with high unmet needs. We recently reported positive","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results"},{"PressReleaseId":"1696","PressReleaseDate":"November 04, 2024","Headline":"Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024","ShortBody":"Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) will report its third quarter 2024 financial results on Thursday, November 7, 2024. Amylyx\u2019 senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (800)-836-8184 (U.S. & Canada) or +1 (646)-357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under \u201cEvents and Presentations\u201d in the Investor section of the Company\u2019s website, https:\/\/investors.amylyx.com\/news-events\/events . The webcast will be archived and available for replay for 90 days following the event. About Amylyx Pharmaceuticals Amylyx is committed to the discovery and development of new treatment options for communities with high unmet needs, including people living with serious and fatal","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-to-report-third-quarter-2024-financial-results-on-november-7-2024"},{"PressReleaseId":"1676","PressReleaseDate":"October 17, 2024","Headline":"Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome","ShortBody":"- Improvement observed in pancreatic function, as measured by C-peptide response, following 24 weeks of treatment with AMX0035; worsening is typically expected with disease progression based on natural history studies of Wolfram syndrome - Longer-term data for all participants who have completed Week 36 and Week 48 assessments showed sustained improvement over time - Improvements or stabilization observed across all secondary endpoints, including measures of glycemic control, vision, and patient- and clinician-reported impressions of overall disease burden - AMX0035 was generally well-tolerated in all participants - Amylyx plans to meet with the FDA and other stakeholders to inform a Phase 3 program and expects to provide an update in 2025 - Topline data to be presented during a live webcast today at 1:30 p.m. ET Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today announced positive topline data from the Phase 2 open-label HELIOS clinical trial of AMX0035","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-announces-positive-topline-results-from-phase-2-helios-clinical-trial-demonstrating-sustained-improvements-with-amx0035-in-people-living-with-wolfram-syndrome"},{"PressReleaseId":"1666","PressReleaseDate":"October 15, 2024","Headline":"Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024","ShortBody":"Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today announced the Company will host a virtual webcast on October 17, 2024 at 1:30 p.m. ET with management and Fumihiko Urano, MD, PhD, principal investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis (WashU Medicine), to discuss topline results from HELIOS, a Phase 2 trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) for the investigational treatment of Wolfram syndrome. The live webcast follows the presentation of these data at the International Society for Pediatric and Adolescent Diabetes 50 th Annual Congress in Lisbon, Portugal. The live webcast can be accessed under \u201cEvents and Presentations\u201d in the Investor section of the Company\u2019s website, https:\/\/investors.amylyx.com\/news-events\/events , and","PressReleaseUrl":"https:\/\/www.amylyx.com\/news\/amylyx-pharmaceuticals-to-host-virtual-webcast-to-discuss-topline-results-from-phase-2-helios-study-of-amx0035-in-wolfram-syndrome-on-october-17-2024"}],"count":144}